Recombinant CD23 (Lumiliximab Biosimilar) antibody

Catalog No. ABIN7543172

This Human Chimeric antibody specifically detects CD23 (Lumiliximab Biosimilar) in FACS and IP. It exhibits reactivity toward Human.

Quick Overview for Recombinant CD23 (Lumiliximab Biosimilar) antibody (ABIN7543172)

Target: CD23 (Lumiliximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human

Clonality: Chimeric

Conjugate: Un-conjugated

Application: Flow Cytometry (FACS), Immunoprecipitation (IP)

Clone: IDEC-152

Product Details

Purpose: Anti-CD23 [IDEC-152 (Lumiliximab, 6G5) ], Human IgG1, kappa

Specificity: This antibody is specific for human CD23.

Characteristics:

Original Species of Ab: Rhesus Macaque

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Immunogen: The original chimeric antibody was generated from a monkey immunized with human CD23. Later on the chimeric version of the antibody was generated by cloning the variable regions of the antibody into human constant regions.

Isotype: IgG1 kappa

Application Details

Application Notes: This antibody is also known as Gomiliximab. It binds CD23 or FCER2, a membrane protein and a "low affinity" receptor for IgE. It is also involved in IgE regulation and inflammation in allergic disorders, such as allergic rhinitis and allergic asthma. Phase I clinical trials in patients with allergic asthma revealed that IDEC-152 is safe and well-tolerated (PMID: 13679816). This antibody is also reported to have antitumor activity against chronic lymphocytic leukemia (CLL) in clinical trials (Woodworth et al., 2004, Byrd et al., 2004). Phase 1 study of Lumiliximab in patients with relapsed or refractory chronic lymphocytic leukemia reported that it was well tolerated and had clinical activity in patients. Flow cytometric analyses of blood samples were conducted to assess changes in lymphocyte subsets and to study both CD23 expression and binding of lumiliximab during the treatment (PMID: 17671129). This antibody also causes apoptosis in vitro and in vivo in CLL cells and drug-resistant lymphoma cells (Pathan et al., 2004, Zou et al., 2004). Lumiliximab was also found to inhibit allergen-induced responses in antigen-presenting cells and may be involved in modulating antigen-presenting cells and reducing T H 2-type immune responses (PMID: 16210051). This antibody was also used in the detection of human CD23 in the B cell-derived exosomes using immunoprecipitation (PMID: 20876574).

Comment:

This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details

Target: CD23 (Lumiliximab Biosimilar)

Target Type: Biosimilar

Background: Gomiliximab, FCER2, BLAST-2, FcεRII, Fc-epsilon-RII, Low affinity immunoglobulin epsilon Fc receptor, C-type lectin domain family 4 member J, Immunoglobulin E-binding factor, Lymphocyte IgE receptor

UniProt: P06734